• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

InsightRX Lands $10M for Precision Medicine Dosing at the Point of Care Platform

by Fred Pennic 09/19/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

– InsightRX raises $10M led by HealthX Ventures to accelerate the adoption of its precision dosing at the point of care platform.


– The platform leverages patient-specific data, pharmacology models, and machine learning to understand each patient’s unique pharmacological profile to guide treatment decisions.


– InsightRX plans to use the new funding to deepen its integration capabilities, broaden development across additional therapeutic areas, and continue its expansion into health systems and life science companies.


InsightRX, a San Francisco, CA-based healthcare technology startup dedicated to helping clinicians individualize medication dosing at the point of care announced today it has raised $10 million in Series A funding. The funding was led by HealthX Ventures, with participation from Rock Health, OSF Healthcare, Leawood Venture Capital, Premier Inc., and earlier investor GreatPoint Ventures. The latest round brings the company’s total funding to date at $13M.

Accelerating Adoption of Precision Dosing Nationwide

Founded in 2015 by Ron Keizer, Sirj Goswami, and Ranvir Mangat, InsightRX has created an integrated clinical decision support platform that individualizes treatment at the point of care. InsightRX leverages patient-specific data and pharmacology models to understand patients’ unique pharmacological profiles and, ultimately, determine appropriate dosing regimens. 

InsightRX Nova

The company’s cloud-based precision dosing platform, InsightRX Nova©, seamlessly integrates with hospital electronic health record (EHR) systems and enables clinicians to individualize medication dosing regimens at the bedside. InsightRX leverages patient-specific data, quantitative pharmacology models, and Bayesian forecasting to understand each patient’s pharmacological profile to guide treatment decisions. The quantitative pharmacology models are continuously improved over time using real-world clinical data and human-assisted artificial intelligence processes that leverage the team’s deep pharmacology expertise and various machine learning and modeling techniques. Currently, InsightRX Nova optimizes treatment across more than 100 drug and therapeutic areas, including oncology and infectious disease.

Clinical Analytics in Real-Time

InsightRX Raises $10 Million to Enable Precision Dosing at Point of Care

Additionally, with the aggregated analytics provided by InsightRX Apollo, hospitals and care teams are able to improve treatment responses and discover novel factors that impact drug efficacy and toxicity. The Nova and Apollo platforms are used by more than a hundred healthcare institutions and life science companies throughout the US and Europe.

InsightRX also partners with leading biopharma companies to develop drug-specific companion applications for use in clinical trials. The ultimate goal is to include the IRX companion application as part of the drug label, accelerating the adoption of precision dosing on a global scale.

Expansion Plans

InsightRX plans to use the new funding to deepen its integration capabilities, broaden development across additional therapeutic areas, and continue its expansion into health systems and life science companies. This past March, InsightRX partnered with the Children’s Hospital Los Angeles (CHLA) to bring precision dosing to clinicians, with the company incorporating CHLA’s technology into its Nova platform.

“Precision dosing allows us to best achieve optimal therapeutic targets for each patient. This is especially important for many medications used in hospitalized infants and children who have highly variable concentrations after standard dosing—concentrations often below or above what is considered safe and effective,” said Dr. Michael Neely, Chief of Infectious Disease at CHLA. “As such, it is important to account for individual patient characteristics to maximize the chances of treatment success while minimizing toxicity.”

Why It Matters

“The future of healthcare relies on individualizing therapy and improving patient outcomes by providing clinicians with tools to make better treatment decisions,” said Sirj Goswami, co-founder and CEO of InsightRX. “Our platform individualizes dosing at the point of care and establishes a data-driven framework to continuously learn about treatment effectiveness—and the underlying factors influencing drug response.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, care teams, Clinical Decision Support, cloud, decision support, Electronic Health Record, Health Systems, healthcare technology, Healthx, InsightRX, Machine Learning, medication, Oncology, Partners, point of care, Precision Medicine, Premier, Rock Health, SAN FRANCISCO, venture capital

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

5 Ways New Trump Administration Tariffs Are Impacting U.S. Healthcare Now

5 Ways Trump Administration Tariffs Are Impacting U.S. Healthcare Now

iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI

RadNet to Acquire iCAD for $103M in All-Stock Transaction

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |